Table 1.
Characteristics of patients according to the presence or absence of CAD
| Parameters | Non-CAD | CAD | P |
|---|---|---|---|
| n (male/female) |
84 (43/41) |
228 (163/65) |
0.001 |
| Age, years |
64.0 ± 9.9 |
67.0 ± 10.0 |
0.018 |
| Body mass index, kg/m2 |
24.8 ± 3.9 |
24.5 ± 3.0 |
0.520 |
| Waist circumference, cm |
89.6 ± 10.9 |
90.6 ±8.9 |
0.408 |
| Fasting plasma glucose, mmol/L |
5.5 (5.0, 6.0) |
5.5 (5.0, 6.4) |
0.448 |
| 2h postprandial glucose, mmol/L |
8.2 (6.2, 9.8) |
8.8 (6.7, 12.4) |
0.031 |
| Glycated hemoglobin A1c, % |
6.0 (5.6, 6.5) |
6.2 (5.8, 6.9) |
0.005 |
| Fasting insulin, mU/L |
16.3(11.9, 22.2) |
16.5 (12.0, 24.5) |
0.431 |
| HOMA-IR |
4.0 (2.8, 6.0) |
4.0(2.8, 5.9) |
0.939 |
| Systolic blood pressure, mmHg |
130.0 (120.0, 150.0) |
130 (120.0, 150.0) |
0.335 |
| Diastolic blood pressure, mmHg |
80.0 (70.0, 85.8) |
80.0 (70.0, 83.8) |
0.569 |
| Total cholesterol, mmol/L |
4.5 ± 1.1 |
4.3 ± 1.1 |
0.070 |
| Triglyceride, mmol/L |
1.5 (1.0, 2.2) |
1.5 (1.1, 2.2) |
0.461 |
| HDL-c, mmol/L |
1.2 ± 0.3 |
1.1 ± 0.3 |
0.018 |
| LDL-c, mmol/L |
3.1 ± 0.9 |
2.9 ± 1.0 |
0.221 |
| C-reactive protein, mg/L |
1.4 (0.6, 3.6) |
1.4 (0.6, 4.0) |
0.329 |
| Adiponectin, μg/mL |
8.4 (5.6, 11,9) |
7.1 (4.7, 12.1) |
0.113 |
| Serum creatinine, μmol/L |
72.0 (61.0, 87.3) |
79.0 (68.0, 91.0) |
0.008 |
| Uric acid, μmol/L |
324.4 ± 85.5 |
352.3 ± 90.6 |
0.392 |
| eGFR, mL/min/1.73m2 |
90.7 ± 25.1 |
85.5 ± 23.2 |
0.092 |
| 24h urine albumin, mg/d |
7.5 (5.1, 14.1) |
7.1 (4.9, 18.3) |
0.775 |
| CAD family history, n (%) |
35 (41.6) |
106 (46.5) |
0.243 |
| Smoking, n (%) |
31 (36.9) |
107 (46.9) |
0.073 |
| Metabolic syndrome, n (%) |
51 (60.7) |
146 (64.0) |
0.340 |
| Central obesity, n (%) |
46 (56.1) |
132 (58.9) |
0.376 |
| Hyperglycemia, n (%) |
51 (60.7) |
147 (64.5) |
0.314 |
| Hypertension, n (%) |
71 (84.5) |
206 (90.4) |
0.109 |
| Hypertriglyceridemia, n (%) |
34 (40.5) |
89 (39.0) |
0.458 |
| Low HDL-c, n (%) |
33 (39.3) |
117 (51.3) |
0.039 |
| Hypoglycemic therapy, n (%) |
12 (14.3) |
60 (26.3) |
0.016 |
| Anti-hypertensive therapy, n (%) |
54 (64.3) |
166 (72.8) |
0.094 |
| Lipid-lowering therapy, n (%) | 11 (13.1) | 80 (35.1) | <0.001 |
Data are mean ± SD or median (interquartile range). CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; LDL-c, low-density lipoprotein cholesterol.